Surveillance of Sentinel Node-Positive Melanoma Patients with Reasons for Exclusion from MSLT-II: Multi-Institutional Propensity Score Matched Analysis https://t.co/TJGifuKZRD https://t.co/jTg6ck8gdQ
RT @JAmCollSurg: MSLT-II trial findings apply to sentinel node positive melanoma patients who were largely excluded, suggesting surveillanc…
RT @KristyBroman: Thanks for this team effort from 21 centers to address a common dilemma in management of high risk sentinel node positiv…
RT @KristyBroman: Thanks for this team effort from 21 centers to address a common dilemma in management of high risk sentinel node positiv…
RT @KristyBroman: Thanks for this team effort from 21 centers to address a common dilemma in management of high risk sentinel node positiv…
RT @KristyBroman: Thanks for this team effort from 21 centers to address a common dilemma in management of high risk sentinel node positiv…
RT @KristyBroman: Thanks for this team effort from 21 centers to address a common dilemma in management of high risk sentinel node positiv…
RT @KristyBroman: Thanks for this team effort from 21 centers to address a common dilemma in management of high risk sentinel node positiv…
RT @JAmCollSurg: MSLT-II trial findings apply to sentinel node positive melanoma patients who were largely excluded, suggesting surveillanc…
RT @KristyBroman: Thanks for this team effort from 21 centers to address a common dilemma in management of high risk sentinel node positiv…
RT @KristyBroman: Thanks for this team effort from 21 centers to address a common dilemma in management of high risk sentinel node positiv…
RT @KristyBroman: Thanks for this team effort from 21 centers to address a common dilemma in management of high risk sentinel node positiv…
RT @JAmCollSurg: MSLT-II trial findings apply to sentinel node positive melanoma patients who were largely excluded, suggesting surveillanc…
RT @KristyBroman: Thanks for this team effort from 21 centers to address a common dilemma in management of high risk sentinel node positiv…
RT @KristyBroman: Thanks for this team effort from 21 centers to address a common dilemma in management of high risk sentinel node positiv…
RT @KristyBroman: Thanks for this team effort from 21 centers to address a common dilemma in management of high risk sentinel node positiv…
RT @KristyBroman: Thanks for this team effort from 21 centers to address a common dilemma in management of high risk sentinel node positiv…
Thanks for this team effort from 21 centers to address a common dilemma in management of high risk sentinel node positive melanoma patients @MoffittNews @USouthFlorida @tashahughesmd @umichsurgery @leslydossett @jamessunmd @mikejcarr @sloan_kettering @Mel
Congrats Dr. Broman!
RT @JAmCollSurg: MSLT-II trial findings apply to sentinel node positive melanoma patients who were largely excluded, suggesting surveillanc…
MSLT-II trial findings apply to sentinel node positive melanoma patients who were largely excluded, suggesting surveillance is an alternative for these patients. https://t.co/Jex7KWcSRr #VisualAbstract #SSA @KristyBroman @MoffittNews #AuthorVideo: https:
New article: Surveillance of Sentinel Node-Positive Melanoma Patients with Reasons for Exclusion From MLST-II: Multi-Institutional Propensity Score Matched Analysis. https://t.co/obKSJ8EvIg #melanoma #oncology https://t.co/8sI3B6ViFO